Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models
- Sarcopenia – age-related loss of muscle mass and strength – affects up to 1 in 5 elderly people globallyi but there are no approved drugs
- The newly-published data validate the predictive value of Rejuvenate Biomed’s proprietary drug discovery platforms and have accelerated the advancement of RJx-01 into an ongoing 6-week placebo-controlled trial in human volunteers
Diepenbeek, Belgium, August 9, 2023 – Rejuvenate Biomed NV (“Rejuvenate”), a clinical-stage company dedicated to the discovery and development of therapeutics to delay the onset of multiple age-related diseases, today announced the publication of RJx-01 efficacy data in two mouse models in JCI Insight, a peer-reviewed journal dedicated to biomedical research.
The paper, titled “A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia,” has been published in collaboration with researchers at the Venetian Institute of Molecular Medicine and Padova University in Italy.
